Literature DB >> 24038799

High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population.

Alicia Semaka1, Chris Kay, Crystal N Doty, Jennifer A Collins, Natalie Tam, Michael R Hayden.   

Abstract

Intermediate alleles (27-35 CAG, IAs) for Huntington disease (HD) usually do not confer the disease phenotype but are prone to CAG repeat instability. Consequently, offspring are at-risk of inheriting an expanded allele in the HD range (≥36 CAG). IAs that expand into a new mutation have been hypothesized to be more susceptible to instability compared to IAs identified on the non-HD side of a family from the general population. Frequency estimates for IAs are limited and have largely been determined using clinical samples of HD or related disorders, which may result in an ascertainment bias. This study aimed to establish the frequency of IAs in a sample of a British Columbia's (B.C.) general population with no known association to HD and examine the haplotype of new mutation and general population IAs. CAG sizing was performed on 1,600 DNA samples from B.C.'s general population. Haplotypes were determined using 22 tagging SNPs across the HTT gene. 5.8% of individuals were found to have an IA, of which 60% were on HD-associated haplotypes. There was no difference in the haplotype distribution of new mutation and general population IAs. These findings suggest that IAs are relatively frequent in the general population and are often found on haplotypes associated with expanded CAG lengths. There is likely no difference in the propensity of new mutation and general population IAs to expand into the disease range given that they are both found on disease-associated haplotypes. These findings have important implications for clinical practice.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CAG repeat instability; Huntington disease; frequency; genetic counseling; haplotype; intermediate alleles; new mutations

Mesh:

Year:  2013        PMID: 24038799     DOI: 10.1002/ajmg.b.32193

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  11 in total

1.  22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium.

Authors:  Sheharyar S Baig; Mark Strong; Elisabeth Rosser; Nicola V Taverner; Ruth Glew; Zosia Miedzybrodzka; Angus Clarke; David Craufurd; Oliver W Quarrell
Journal:  Eur J Hum Genet       Date:  2016-05-11       Impact factor: 4.246

2.  Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

Authors:  Galen E B Wright; Jennifer A Collins; Chris Kay; Cassandra McDonald; Egor Dolzhenko; Qingwen Xia; Kristina Bečanović; Britt I Drögemöller; Alicia Semaka; Charlotte M Nguyen; Brett Trost; Fiona Richards; Emilia K Bijlsma; Ferdinando Squitieri; Colin J D Ross; Stephen W Scherer; Michael A Eberle; Ryan K C Yuen; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2019-05-16       Impact factor: 11.025

3.  In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.

Authors:  Amber L Southwell; Niels H Skotte; Holly B Kordasiewicz; Michael E Østergaard; Andrew T Watt; Jeffrey B Carroll; Crystal N Doty; Erika B Villanueva; Eugenia Petoukhov; Kuljeet Vaid; Yuanyun Xie; Susan M Freier; Eric E Swayze; Punit P Seth; Clarence Frank Bennett; Michael R Hayden
Journal:  Mol Ther       Date:  2014-08-07       Impact factor: 11.454

4.  Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Authors:  Chris Kay; Jennifer A Collins; Zosia Miedzybrodzka; Steven J Madore; Erynn S Gordon; Norman Gerry; Mark Davidson; Ramy A Slama; Michael R Hayden
Journal:  Neurology       Date:  2016-06-22       Impact factor: 9.910

Review 5.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

Review 6.  Biological functions and potential therapeutic applications of huntingtin-associated protein 1: progress and prospects.

Authors:  X Zhao; A Chen; Z Wang; Xiao-Han Xu; Y Tao
Journal:  Clin Transl Oncol       Date:  2021-09-26       Impact factor: 3.405

Review 7.  Distribution of the HTT Gene A1 and A2 Haplotypes Worldwide: A Systematic Review.

Authors:  Thays Andrade Apolinário; Dionatan Costa Rodrigues; Mayra Braga Lemos; Carmen Lúcia Antão Paiva; Luciana Andrade Agostinho
Journal:  Clin Med Res       Date:  2020-09-02

8.  Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability.

Authors:  Makoto Hashimoto; Gilbert Ho; Yoshiki Takamatsu; Ryoko Wada; Shuei Sugama; Takato Takenouchi; Eliezer Masliah; Masaaki Waragai
Journal:  J Huntingtons Dis       Date:  2018

9.  Investigation of intermediate CAG alleles of the HTT in the general population of Rio de Janeiro, Brazil, in comparison with a sample of Huntington disease-affected families.

Authors:  Thays A Apolinário; Iane Dos Santos da Silva; Luciana de Andrade Agostinho; Carmen L A Paiva
Journal:  Mol Genet Genomic Med       Date:  2020-02-17       Impact factor: 2.183

10.  Brain Microbiota in Huntington's Disease Patients.

Authors:  Ruth Alonso; Diana Pisa; Luis Carrasco
Journal:  Front Microbiol       Date:  2019-11-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.